US-FED-00000384269 - NOI - Oxford Nanopore Tech. - PromethION 2 Integrated Instrument - Deadline July 7,2026

This is a Notice of Intent, not a request for quotation (RFQ). A solicitation document will not be issued, and quotations will not be requested.The National Institutes of Health (NIH), Clinical Center, Department of Laboratory Medicine (DLM) intends to award a sole source firm–fixed–price contract to Oxford Nanopore Technologies Inc. for the procurement of PromethION 2 Integrated Instrument.The purpose of this procurement is to secure Oxford Nanopore PromethION 2 Integrated instrument to be used to perform long read genomic DNA sequencing of patient samples to detect DNA mutations, DNA structural abnormalities (e.g., deletions, insertions, and inversions, etc.), and DNA methylation that are often undetected by commonly used DNA sequencing techniques in the hematology clinical research lab.The Oxford Nanopore PromethION 2 Integrated instrument will be used to perform long read genomic DNA sequencing of patient samples to detect DNA mutations, DNA structural abnormalities (e.g., deletions, insertions, and inversions, etc.), and DNA methylation that are often undetected by commonly used DNA sequencing techniques. Oxford Nanopore is the original instrument and reagent manufacturer and is the only vendor with the capacity of performing these kinds of tests. After research validation of the tests, the reagents could be used to validate the patient testing system according to regulatory and accreditation requirements. It is therefore deemed to be in the Government`s best interest that this instrument is procured from Oxford Nanopore.The Department of Laboratory Medicine serves as the clinical laboratory of the NIH Clinical Center. It provides laboratory support for patient care and research protocols and performs research and training in disciplines of Clinical Hematological Pathology. In doing so it provides state–of–the–art laboratory testing in support of Clinical Center patient care and serves as a center of excellence in research and training in laboratory medicine, particularly in areas which utilize the unique strengths of the National Institutes of Health.BackgroundThe Department of Laboratory Medicine serves as the clinical laboratory of the NIH Clinical Center. It provides laboratory support for patient care and research protocols and performs research and training in disciplines of Clinical Hematological Pathology.Rationale:Oxford Nanopore is the original instrument manufacturer and sole vendor for instruments of these kinds of tests, i.e., long read sequencing to detect DNA mutations, DNA structural abnormalities (e.g., deletions, insertions, and inversions, etc.), and DNA methylation from patient samples. It is advisable to use Oxford Nanopore long–read sequencing for testing of samples from patients with cancer, cancer predisposing disorders, and with complicated clinical and pathological phenotypes.AuthorityThis acquisition is being conducted in accordance with:FAR 13.106–1(b)(1) Soliciting from a Single SourceUnder this authority, the Contracting Officer may solicit from a single source when it is determined that only one source is reasonably available to meet the Government`s requirements.Acquisitions conducted under FAR Part 13 Simplified AcquisitionProcedures are exempt from the competition requirements of FAR Part 6.ResponsesThis is not a request for quotations. However, interested parties may submit a capability statement demonstrating their ability to meet the Government`s requirement.Responses must include:Company name and addressTechnical capability